<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
    <front>
        <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id><journal-id journal-id-type="pmc">ploscomp</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Computational Biology</journal-title></journal-title-group><issn pub-type="ppub">1553-734X</issn><issn pub-type="epub">1553-7358</issn><publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, USA</publisher-loc>
            </publisher></journal-meta>
        <article-meta><article-id pub-id-type="publisher-id">10-PLCB-RA-2839R2</article-id><article-id pub-id-type="doi">10.1371/journal.pcbi.1001113</article-id><article-categories>
                <subj-group subj-group-type="heading">
                    <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline">
                    <subject>Computational Biology</subject>
                    <subject>Computational Biology/Systems Biology</subject>
                    <subject>Oncology/Oncology Agents</subject>
                </subj-group>
            </article-categories><title-group><article-title>Consensus-Phenotype Integration of Transcriptomic and Metabolomic Data Implies a Role for Metabolism in the Chemosensitivity of Tumour Cells</article-title><alt-title alt-title-type="running-head">Consensus-Phenotype Integration</alt-title></title-group><contrib-group>
                <contrib contrib-type="author" xlink:type="simple">
                    <name name-style="western">
                        <surname>Cavill</surname>
                        <given-names>Rachel</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
                </contrib>
                <contrib contrib-type="author" xlink:type="simple">
                    <name name-style="western">
                        <surname>Kamburov</surname>
                        <given-names>Atanas</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
                </contrib>
                <contrib contrib-type="author" xlink:type="simple">
                    <name name-style="western">
                        <surname>Ellis</surname>
                        <given-names>James K.</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
                </contrib>
                <contrib contrib-type="author" xlink:type="simple">
                    <name name-style="western">
                        <surname>Athersuch</surname>
                        <given-names>Toby J.</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
                    <xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
                </contrib>
                <contrib contrib-type="author" xlink:type="simple">
                    <name name-style="western">
                        <surname>Blagrove</surname>
                        <given-names>Marcus S. C.</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
                </contrib>
                <contrib contrib-type="author" xlink:type="simple">
                    <name name-style="western">
                        <surname>Herwig</surname>
                        <given-names>Ralf</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
                </contrib>
                <contrib contrib-type="author" xlink:type="simple">
                    <name name-style="western">
                        <surname>Ebbels</surname>
                        <given-names>Timothy M. D.</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
                    <xref ref-type="corresp" rid="cor1"><sup>*</sup></xref>
                </contrib>
                <contrib contrib-type="author" xlink:type="simple">
                    <name name-style="western">
                        <surname>Keun</surname>
                        <given-names>Hector C.</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
                    <xref ref-type="corresp" rid="cor1"><sup>*</sup></xref>
                </contrib>
            </contrib-group><aff id="aff1"><label>1</label><addr-line>Biomolecular Medicine, Department of Surgery
                    and Cancer, Faculty of Medicine, Imperial College London, London, United
                    Kingdom</addr-line>
            </aff><aff id="aff2"><label>2</label><addr-line>Max Planck Institute for Molecular Genetics,
                    Berlin, Germany</addr-line>
            </aff><aff id="aff3"><label>3</label><addr-line>MRC-HPA Centre for Environment and Health,
                    Department of Epidemiology and Biostatistics, School of Public Health, Faculty
                    of Medicine, Imperial College London, London, United Kingdom</addr-line>
            </aff><aff id="aff4"><label>4</label><addr-line>Department of Zoology, Oxford University,
                    Oxford, United Kingdom</addr-line>
            </aff><contrib-group>
                <contrib contrib-type="editor" xlink:type="simple">
                    <name name-style="western">
                        <surname>Tucker-Kellogg</surname>
                        <given-names>Greg</given-names>
                    </name>
                    <role>Editor</role>
                    <xref ref-type="aff" rid="edit1"/>
                </contrib>
            </contrib-group><aff id="edit1">Lilly Singapore Centre for Drug Discovery, Singapore</aff><author-notes>
                <corresp id="cor1">* E-mail: <email xlink:type="simple">h.keun@imperial.ac.uk</email> (HCK); <email xlink:type="simple">t.ebbels@imperial.ac.uk</email> (TMDE)</corresp>
                <fn fn-type="con">
                    <p>Conceived and designed the experiments: TMDE HCK. Analyzed the data: RC MSCB.
                        Contributed reagents/materials/analysis tools: RC AK RH. Wrote the paper: RC
                        JKE TJA TMDE HCK.</p>
                </fn>
            <fn fn-type="conflict">
                <p>The authors have declared that no competing interests exist.</p>
            </fn></author-notes><pub-date pub-type="collection">
                <month>3</month>
                <year>2011</year>
            </pub-date><pub-date pub-type="epub">
                <day>31</day>
                <month>3</month>
                <year>2011</year>
            </pub-date><volume>7</volume><issue>3</issue><elocation-id>e1001113</elocation-id><history>
                <date date-type="received">
                    <day>1</day>
                    <month>10</month>
                    <year>2010</year>
                </date>
                <date date-type="accepted">
                    <day>25</day>
                    <month>2</month>
                    <year>2011</year>
                </date>
            </history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2011</copyright-year><copyright-holder>Cavill et al</copyright-holder><license><license-p>This is an open-access article distributed under the
                terms of the Creative Commons Attribution License, which permits unrestricted use,
                distribution, and reproduction in any medium, provided the original author and
                source are credited.</license-p></license></permissions><abstract>
                <p>Using transcriptomic and metabolomic measurements from the NCI60 cell line panel,
                    together with a novel approach to integration of molecular profile data, we show
                    that the biochemical pathways associated with tumour cell chemosensitivity to
                    platinum-based drugs are highly coincident, i.e. they describe a consensus
                    phenotype. Direct integration of metabolome and transcriptome data at the point
                    of pathway analysis improved the detection of consensus pathways by 76%,
                    and revealed associations between platinum sensitivity and several metabolic
                    pathways that were not visible from transcriptome analysis alone. These pathways
                    included the TCA cycle and pyruvate metabolism, lipoprotein uptake and
                    nucleotide synthesis by both salvage and de novo pathways. Extending the
                    approach across a wide panel of chemotherapeutics, we confirmed the specificity
                    of the metabolic pathway associations to platinum sensitivity. We conclude that
                    metabolic phenotyping could play a role in predicting response to platinum
                    chemotherapy and that consensus-phenotype integration of molecular profiling
                    data is a powerful and versatile tool for both biomarker discovery and for
                    exploring the complex relationships between biological pathways and drug
                    response.</p>
            </abstract><abstract abstract-type="summary">
                <title>Author Summary</title>
                <p>Resistance to chemotherapy drugs in cancer sufferers is very common. Using a
                    panel of 59 cell lines obtained from different types of cancer we study the
                    links between the genes and metabolites measured in these cells and the
                    resistance the cells show to common cancer drugs containing platinum. In order
                    to combine the information given by the genes and metabolites we introduce a new
                    pathway-based approach, which allows us to explore synergy between the different
                    types of data. We then extend the procedure to look at a wider panel of drugs
                    and show that the pathways we found were associated with platinum are not just
                    the pathways which are frequently selected for a large number of drugs. Given
                    the increasing use of multiple sets of measurements (genes, metabolites,
                    proteins etc.) in biological studies, we demonstrate a powerful, yet
                    straightforward method for dealing with the resulting large datasets and
                    integrating their knowledge. We believe that this work could contribute to
                    developing a personalised medicine approach to treating tumours, where the
                    genetic and metabolic changes in the tumour are measured and then used for
                    prediction of the optimal treatment regime.</p>
            </abstract><funding-group><funding-statement>We acknowledge funding from the EU CarcinoGENOMICS consortium, contract No.
                    PL037712, in support of this work. Atanas Kamburov receives support from the EU
                    APO-SYS project (HEALTH-F4-2007-200767) and Ralf Herwig from the BMBF PREDICT
                    project (0315428A). The funders had no role in study design, data collection and
                    analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts>
                <page-count count="12"/>
            </counts></article-meta>
    </front>
    <body>
        <sec id="s1">
            <title>Introduction</title>
            <p>In the quest to understand complex biological systems at multiple levels of
                biological organization, the need arises to combine knowledge from experiments of
                different types to create a full picture of a system's behavior. Modern
                molecular profiling (“omics”) methods, such as transcriptomics,
                proteomics and metabolomics allow one to build up a global picture of system
                characteristics, and to search for interactions and coordinated behavior between the
                different levels. While each level can be studied separately, greater statistical
                and explanatory power can be gained by integrating this knowledge into a single
                coherent model of the system. This is currently one of the greatest challenges in
                systems biology.</p>
            <p>Inter-omic data integration can be performed at different levels <xref ref-type="bibr" rid="pcbi.1001113-Ebbels1">[1]</xref>, the simplest of
                which is conceptual integration. At this level, each omics data set is analysed
                separately and a coherent biological rationale is constructed which explains
                phenomena observed in the separate molecular profiles. For example, changes in
                levels of both enzyme transcripts and metabolites from the same pathway could be
                explained by the hypothesis of differential regulation of that pathway. However this
                subjective approach can lead to plausible biological explanations that arise through
                spurious statistical associations and conversely some potentially novel mechanisms
                may be overlooked. The statistical level of integration is more objective. In this
                approach, links between data sets are made using rigorous statistical procedures
                such as correlation, regression or more sophisticated techniques. To date, much
                inter-omic data integration has been performed at the conceptual level <xref ref-type="bibr" rid="pcbi.1001113-Craig1">[2]</xref>, <xref ref-type="bibr" rid="pcbi.1001113-Hirai1">[3]</xref>, <xref ref-type="bibr" rid="pcbi.1001113-Heijne1">[4]</xref> while various
                methods have been proposed and demonstrated for statistical integration <xref ref-type="bibr" rid="pcbi.1001113-Lanckriet1">[5]</xref>, <xref ref-type="bibr" rid="pcbi.1001113-Rantalainen1">[6]</xref>, <xref ref-type="bibr" rid="pcbi.1001113-Joyce1">[7]</xref>, <xref ref-type="bibr" rid="pcbi.1001113-Bylesjo1">[8]</xref>, <xref ref-type="bibr" rid="pcbi.1001113-Dumas1">[9]</xref>.</p>
            <p>Many researchers have found that interpretation of omics data at the level of
                individual molecular entities can be difficult and have opted for an analysis at the
                pathway or functional level <xref ref-type="bibr" rid="pcbi.1001113-Chuang1">[10]</xref>. This is mainly because particular changes in biochemical
                pathways, associated with phenotypic conditions such as disease can often arise from
                a range of different alterations in a pathway. A common method for performing
                pathway-level analysis on single omic data is over-representation (OR) analysis
                    <xref ref-type="bibr" rid="pcbi.1001113-Tavazoie1">[11]</xref>, <xref ref-type="bibr" rid="pcbi.1001113-Curtis1">[12]</xref>, in which a set
                of molecular elements (e.g. genes) that are differentially expressed or correlated
                with the phenotype of interest are first selected. The set is then compared against
                molecular sets defined <italic>a priori</italic> (e.g. genes in established
                pathways) to identify those sets that show greater overlap with the
                phenotype-associated genes than would be expected by chance. The final list of
                significantly over-represented or ‘enriched’ sets/pathways is used to
                aid biological interpretation of the data. As well as performing OR with genes,
                Metabolite Set Enrichment Analysis (MSEA) <xref ref-type="bibr" rid="pcbi.1001113-Xia1">[13]</xref> and other metabolite
                over-representation techniques <xref ref-type="bibr" rid="pcbi.1001113-Sabatine1">[14]</xref> have also been developed. In this work we contrast the
                application of the OR analysis approach to transcript and metabolite data
                individually to the alternative of considering them simultaneously, using
                established pathways to guide an integrated analysis of the two data sets.</p>
            <p>In addition to the inter-omic integration of metabolomic and transcriptomic data, our
                approach involves a further type of data integration that we call
                consensus-phenotype integration. In this approach, several examples of the same
                phenotype, achieved in different ways, are used within the experimental design. For
                example, one may study a particular mechanism of toxicity via the use of different
                chemical treatments that have a similar mode of action. One can thus identify
                features that are central to the phenotype in question across different types of
                “omics” data, as opposed to features that are specific to a single
                instance of the phenotype being studied.</p>
            <p>In this work, we aim to elucidate mechanisms of drug sensitivity through the use of
                inter-omic statistical data integration using drug sensitivity, transcriptomic and
                metabolomic data from the NCI60 cell line panel <xref ref-type="bibr" rid="pcbi.1001113-Scherf1">[15]</xref>. The NCI60 is a panel of tumor
                derived cell lines corresponding to diverse tissue types, which has been subject to
                extensive molecular phenotypic and pharmacological characterization. We used
                baseline (untreated) metabolic and transcriptional profiles readily available for 58
                lines as well as growth inhibition data from an array of 118 drugs <xref ref-type="bibr" rid="pcbi.1001113-Scherf1">[15]</xref>, <xref ref-type="bibr" rid="pcbi.1001113-Bussey1">[16]</xref>. We correlate
                growth inhibition to the molecular profiles to identify pathways related to drug
                sensitivity. We first focus on platinum sensitivity as it is a well-defined
                phenotype, linked to a well-investigated mode of action that has important clinical
                implications. Many chemotherapeutic regimes are based on platinum compounds, and
                resistance to these drugs is a major obstacle in successful treatment of some
                cancers. The mechanisms that cause variation in response to therapy are not well
                understood, and the ability to predict sensitivity from a baseline profile of the
                tumor would help to improve therapy selection and thereby potentially reduce patient
                morbidity and mortality. We then expand our analysis to a larger set of 118 drugs to
                investigate whether the method is able to associate drugs with similar modes of
                action. We show that statistical integration conducted through a joint analysis of
                the data gives specific advantages in terms of sensitivity and confidence of pathway
                associations.</p>
        </sec>
        <sec id="s2">
            <title>Results</title>
            <p><xref ref-type="fig" rid="pcbi-1001113-g001">Figure 1</xref> shows a schematic
                overview of our data analysis strategy. Whole genome gene expression
                (transcriptomic), metabolomic, and drug sensitivity data were obtained for the NCI60
                tumor cell line panel. The transcriptomics data was derived using the U133
                Affymetrix chip; in total 44928 probesets were measured, equating to 17150 gene
                products mapping to distinct UniProt identifiers, each measured across 58 cell lines
                    <xref ref-type="bibr" rid="pcbi.1001113-Shankavaram1">[17]</xref>. The
                metabolomic data consisted of measurements of the total intracellular abundance of
                154 uniquely identified metabolites across all 58 cell lines <xref ref-type="bibr" rid="pcbi.1001113-Holbeck1">[18]</xref>, including lipid compounds
                (e.g. cholesterol), glycolytic intermediates (e.g. glucose-6-phosphate), nucleic
                acid metabolites (e.g. adenine, uracil, hypoxanthine) and amino acids (e.g.
                glutamate, taurine). The full list along with our assigned KEGG IDs can be obtained
                in <xref ref-type="supplementary-material" rid="pcbi.1001113.s004">Table S4</xref>.
                We used drug sensitivity data (GI<sub>50</sub> values indicating the concentration
                of the drug which inhibited cell growth by 50%) <xref ref-type="bibr" rid="pcbi.1001113-Scherf1">[15]</xref>, <xref ref-type="bibr" rid="pcbi.1001113-Bussey1">[16]</xref> initially for four
                platinum-based chemotherapeutics, cisplatin, carboplatin, tetraplatin and
                iproplatin. Data for a fifth platinum drug (diaminocyclohexyl-Pt(II)) was available,
                and was used at a later stage as a test compound to validate our findings.</p>
            <fig id="pcbi-1001113-g001" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pcbi.1001113.g001</object-id>
                <label>Figure 1</label>
                <caption>
                    <title>Consensus-phenotype integration of transcript and metabolite data: a
                        schematic of the study design.</title>
                </caption>
                <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001113.g001" xlink:type="simple"/>
            </fig>
            <sec id="s2a">
                <title>Identifying pathways significantly associated to platinum sensitivity</title>
                <p>For each drug we ranked all probe sets by their absolute Pearson correlation
                        (|<italic>r</italic>|) to the −log(<italic>GI<sub>50</sub></italic>)
                    values across all cell lines. Setting the false discovery rate (FDR) <xref ref-type="bibr" rid="pcbi.1001113-Benjamini1">[19]</xref> at
                    60% we then selected genes considered to be significantly associated to
                    chemosensitivity. A high FDR was tolerated at this stage of the analysis to
                    ensure that subsequent pathway analysis was adequately powered. Repeating this
                    process for the metabolite data we obtained separate panels of genes and
                    metabolites that were deemed to be associated with the sensitivity to each drug
                    (see <xref ref-type="supplementary-material" rid="pcbi.1001113.s001">Table
                        S1</xref>). In total 3, 33, 37 and 92 metabolites and 915, 1620, 5035 &amp;
                    6533 genes were identified as associated with sensitivity to carboplatin,
                    cisplain, iproplatin and tetraplatin treatment respectively.</p>
                <p>To assess which pathways characterized the drug sensitivity phenotype we then
                    performed OR analysis with pathways from the ConsensusPathDB <xref ref-type="bibr" rid="pcbi.1001113-Kamburov1">[20]</xref>. The
                    ConsensusPathDB collates pathways from several public databases of protein
                    interactions, signaling and metabolic pathways as well as gene regulation in
                    humans. We restricted our analysis to sources covering biochemical reactions:
                    KEGG <xref ref-type="bibr" rid="pcbi.1001113-Kanehisa1">[21]</xref>,
                    Reactome <xref ref-type="bibr" rid="pcbi.1001113-JoshiTope1">[22]</xref>, Netpath (<ext-link ext-link-type="uri" xlink:href="http://www.netpath.org" xlink:type="simple">http://www.netpath.org</ext-link>),
                    Biocarta (<ext-link ext-link-type="uri" xlink:href="http://www.biocarta.com" xlink:type="simple">http://www.biocarta.com</ext-link>), HumanCyc <xref ref-type="bibr" rid="pcbi.1001113-Romero1">[23]</xref> and the pathway interaction
                    database (PID) <xref ref-type="bibr" rid="pcbi.1001113-Schaefer1">[24]</xref>. The use of multiple databases reduces bias by
                    enhancing coverage. At the time of analysis the ConsensusPathDB contained 1875
                    pathways from the selected sources, of which 1651 contain at least one gene and
                    581 contain at least one metabolite measured in the NCI60 data (excluding the
                    highly prevalent ‘currency’ metabolites phosphate, diphosphate and
                    NADP+). OR analysis of the phenotype-associated gene panels indicated that
                    63, 74, 233 and 242 pathways were associated with cisplatin, carboplatin,
                    iproplatin and tetraplatin sensitivity respectively (p&lt;0.05). The equivalent
                    analysis for metabolite panels indicated that 24, 13, 4, &amp; 5 pathways were
                    associated with these phenotypes.</p>
            </sec>
            <sec id="s2b">
                <title>Consensus pathway and inter-omic integration</title>
                <p>To highlight pathways relevant to general platinum sensitivity, as opposed to
                    particular platinum compounds, we looked for pathways that were associated with
                    more than one drug response phenotype (‘consensus-phenotype
                    integration’; <xref ref-type="fig" rid="pcbi-1001113-g002">Figure 2 A
                        &amp; B</xref>). Within the gene transcript analysis (<xref ref-type="fig" rid="pcbi-1001113-g002">Figure 2A</xref>), the drugs appeared to divide into
                    two pairs that shared many pathways in common. Iproplatin and tetraplatin were
                    most similar, sharing 143 (133+4+4+2) of the 330
                    (75+5+5+4+143+92+3+1+2), ie. 43%
                    of the pathways associated with either drug (<xref ref-type="fig" rid="pcbi-1001113-g002">Figure 2A</xref>). Carboplatin and cisplatin also
                    show a high level of similarity (32 of 103 pathways, 31%). In the
                    metabolic analysis (<xref ref-type="fig" rid="pcbi-1001113-g002">Figure
                        2B</xref>) the similarity between iproplatin and tetraplatin was much lower,
                    while carboplatin and cisplatin retained a high level of similarity with 7 of
                    the 30 pathways being shared (23%). The gene analysis highlights many
                    more pathways than metabolite analysis due to both the higher number of pathways
                    with sufficient numbers of quantified transcripts and the limited number of
                    quantified and identified metabolites.</p>
                <fig id="pcbi-1001113-g002" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pcbi.1001113.g002</object-id>
                    <label>Figure 2</label>
                    <caption>
                        <title>Consensus-phenotype and inter-omic integration at the pathway
                            level.</title>
                        <p>The numbers of common pathways significantly over-represented for each
                            compound are shown as Venn diagrams. A transcript data, B metabolite
                            data, C inter-omic analysis using both metabolite and transcript data
                            and D comparison of the three approaches using pathways which are
                            significant for at least three drugs. (All Venn diagrams produced by
                                <bold>Venny </bold><xref ref-type="bibr" rid="pcbi.1001113-Oliveros1">[<bold>55</bold>]</xref>).</p>
                    </caption>
                    <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001113.g002" xlink:type="simple"/>
                </fig>
                <p>We next combined the transcriptomic and metabolomic data into a joint inter-omic
                    OR analysis (<xref ref-type="fig" rid="pcbi-1001113-g002">Figure 2C</xref>) by
                    estimating the joint probability of association of each pathway with the drug
                    sensitivity phenotype assuming independence between the probability of
                    association from the gene and metabolite data separately (see <xref ref-type="sec" rid="s4">Methods</xref>). 35 pathways were found to be
                    significant for at least one drug in the joint analysis that did not feature in
                    either of the separate analyses of gene expression or metabolite levels. To
                    confirm the significance of the increase in pathway detection after integration
                    of the metabolic and transcriptomic data, we estimated the null distribution of
                    the joint analysis probabilities by permuting the gene analysis pathway
                    probabilities relative to the metabolite analysis pathway probabilities. For
                    carboplatin only 3 of the 100 permutations produced more pathways than the real
                    data and for cisplatin no permutations produced as many pathways as the real
                    data. However, for iproplatin and tetraplatin, the number of pathways detected
                    was not significantly enhanced by the joint OR analysis, suggesting that the
                    combined analysis may be most advantageous when the numbers of significantly
                    associated genes or metabolites are relatively low.</p>
                <p>To examine the significance of the numbers of pathways in the joint OR analysis
                    that were commonly associated to the effect of multiple drug treatments, two
                    null models were generated. Null model I assumed that genes and metabolites
                    identified as significantly associated to a phenotype were randomly selected
                    whereas null model II correspondingly assumed that pathways are selected
                    randomly. <xref ref-type="table" rid="pcbi-1001113-t001">Table 1</xref>
                    summarizes the pathway coincidence between the output of joint OR analysis
                    across the four platinum drugs for these two null models compared to the real
                    data and reports the associated FDR in each analysis. We observed that by
                    setting our criterion of significant association between a pathway and platinum
                    sensitivity at requiring a majority of the drugs to be associated with that
                    pathway (i.e. at least 3/4) we achieved acceptable FDRs of 0.2% (null
                    model I) and 16.9% (null model II, the most extreme scenario).</p>
                <table-wrap id="pcbi-1001113-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1001113.t001</object-id><label>Table 1</label><caption>
                        <title>Null models I and II.</title>
                    </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pcbi-1001113-t001-1" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001113.t001" xlink:type="simple"/><table>
                        <colgroup span="1">
                            <col align="left" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                        </colgroup>
                        <thead>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="4" rowspan="1">Number of pathways common to exactly
                                        <italic>n</italic> drugs and FDR</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Number of drugs, <italic>n</italic></td>
                                <td align="left" colspan="1" rowspan="1">1</td>
                                <td align="left" colspan="1" rowspan="1">2</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">4</td>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"><bold>Real data (inter-omic analysis)</bold></td>
                                <td align="left" colspan="1" rowspan="1">251</td>
                                <td align="left" colspan="1" rowspan="1">182</td>
                                <td align="left" colspan="1" rowspan="1">24</td>
                                <td align="left" colspan="1" rowspan="1">6</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"><bold>Null model I</bold></td>
                                <td align="left" colspan="1" rowspan="1">161.8</td>
                                <td align="left" colspan="1" rowspan="1">6.6</td>
                                <td align="left" colspan="1" rowspan="1">0.06</td>
                                <td align="left" colspan="1" rowspan="1">0.0</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"><bold>Cumulative false discovery rate</bold></td>
                                <td align="left" colspan="1" rowspan="1">36.4%</td>
                                <td align="left" colspan="1" rowspan="1">3.2%</td>
                                <td align="left" colspan="1" rowspan="1">0.2%</td>
                                <td align="left" colspan="1" rowspan="1">0.0%</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"><bold>Null model II</bold></td>
                                <td align="left" colspan="1" rowspan="1">539.3</td>
                                <td align="left" colspan="1" rowspan="1">81.2</td>
                                <td align="left" colspan="1" rowspan="1">5.0</td>
                                <td align="left" colspan="1" rowspan="1">0.1</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"><bold>Cumulative false discovery rate</bold></td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">40.7%</td>
                                <td align="left" colspan="1" rowspan="1">16.9%</td>
                                <td align="left" colspan="1" rowspan="1">&lt;0.1%</td>
                            </tr>
                        </tbody>
                    </table></alternatives><table-wrap-foot>
                        <fn id="nt101">
                            <label/>
                            <p>The numbers of pathways associated with exactly <italic>n</italic>
                                drugs for each of the null models and in real data.</p>
                        </fn>
                    </table-wrap-foot></table-wrap>
                <p>Using the majority overlap criterion we compared the number of pathways
                    consistently associated with platinum sensitivity between the individual and
                    joint analyses (<xref ref-type="fig" rid="pcbi-1001113-g002">Figure 2D</xref>).
                    The joint OR analysis identified all pathways highlighted by the individual
                    –omic OR analyses combined (17 in total), but also indicated a further 13
                    pathways that were consistently associated (+76%). No pathways were
                    found to be common between both the separate gene and metabolite analyses.</p>
                <p>Overall 30 pathways met the majority criterion of association with sensitivity at
                    least 3 platinum drugs and hence general platinum cytotoxicity (<xref ref-type="table" rid="pcbi-1001113-t002">Table 2</xref>; <xref ref-type="fig" rid="pcbi-1001113-g002">Figure 2C &amp; D</xref>). All the
                    databases used to compile the ConsensusPathDB contributed pathways to the final
                    selected consensus pathways, highlighting the value of the ConsensusPathDB
                    strategy in pathway analysis. While this subset of pathways included those with
                    established relationships to platinum sensitivity and general chemosensitivity,
                    such as DNA repair and Akt regulation of nuclear transcription, there were also
                    several pathways related to metabolic processes not previously reported as
                    determinants of platinum sensitivity. These included nucleotide metabolism,
                    fatty acid, triglyceride and lipid metabolism.</p>
                <table-wrap id="pcbi-1001113-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1001113.t002</object-id><label>Table 2</label><caption>
                        <title>Pathways significant by over representation analysis with respect to
                            platinum drug sensitivity.</title>
                    </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pcbi-1001113-t002-2" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001113.t002" xlink:type="simple"/><table>
                        <colgroup span="1">
                            <col align="left" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                        </colgroup>
                        <thead>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="2" rowspan="1">Effective size of pathway in terms
                                    of…</td>
                                <td align="left" colspan="3" rowspan="1">Number of drugs with this pathway
                                    over-represented in…</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Pathway and <italic>source database</italic></td>
                                <td align="left" colspan="1" rowspan="1">genes</td>
                                <td align="left" colspan="1" rowspan="1">metabolites</td>
                                <td align="left" colspan="1" rowspan="1">Inter-omic analysis</td>
                                <td align="left" colspan="1" rowspan="1">gene analysis</td>
                                <td align="left" colspan="1" rowspan="1">metabolite analysis</td>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"><bold>Metabolic Pathways</bold></td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1"/>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1"><bold>22</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>2</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>3</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>2</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>0</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"><bold>Triacylglyceride Biosynthesis
                                            </bold><bold><italic>Reactome</italic></bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>29</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>3</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>4</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>3</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>0</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"><bold>Purine metabolism
                                            </bold><bold><italic>Reactome</italic></bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>82</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>16</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>3</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>2</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>1</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"><bold>Purine metabolism - Homo sapiens (human)
                                            </bold><bold><italic>KEGG</italic></bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>412</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>19</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>3</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>2</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>1</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"><bold>DNA Repair
                                            </bold><bold><italic>Reactome</italic></bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>144</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>5</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>3</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>1</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>1</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"><bold>Hormone-sensitive lipase (HSL)-mediated
                                        triacylglycerol hydrolysis
                                            </bold><bold><italic>Reactome</italic></bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>23</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>2</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>3</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>1</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>2</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"><bold>Lipid and lipoprotein metabolism
                                            </bold><bold><italic>Reactome</italic></bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>243</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>9</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>3</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>2</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>0</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"><bold>De novo biosynthesis of pyrimidine
                                        deoxyribonucleotides
                                        </bold><bold><italic>HumanCyc</italic></bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>17</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>1</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>3</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>1</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>0</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"><bold>Salvage pathways of purine and pyrimidine
                                        nucleotides
                                    </bold><bold><italic>HumanCyc</italic></bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>45</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>9</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>3</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>1</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>0</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"><bold>Phosphatidylcholine biosynthesis pathway
                                            </bold><bold><italic>BioCarta</italic></bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>6</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>1</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>3</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>2</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>0</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Base Excision Repair <italic>Reactome</italic></td>
                                <td align="left" colspan="1" rowspan="1">27</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">4</td>
                                <td align="left" colspan="1" rowspan="1">2</td>
                                <td align="left" colspan="1" rowspan="1">2</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Nucleotide metabolism
                                    <italic>Reactome</italic></td>
                                <td align="left" colspan="1" rowspan="1">137</td>
                                <td align="left" colspan="1" rowspan="1">27</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">2</td>
                                <td align="left" colspan="1" rowspan="1">1</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Pyruvate metabolism and TCA cycle
                                        <italic>Reactome</italic></td>
                                <td align="left" colspan="1" rowspan="1">52</td>
                                <td align="left" colspan="1" rowspan="1">6</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">0</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Reversible phosphorolysis of pyrimidine nucleosides
                                        <italic>Reactome</italic></td>
                                <td align="left" colspan="1" rowspan="1">2</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">0</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Phospholipid biosynthesis II
                                        <italic>HumanCyc</italic></td>
                                <td align="left" colspan="1" rowspan="1">57</td>
                                <td align="left" colspan="1" rowspan="1">4</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">0</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"><bold>Non-Metabolic pathways</bold></td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1"/>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"><bold>Signaling in Immune system
                                            </bold><bold><italic>Reactome</italic></bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>467</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>1</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>3</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>2</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>0</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"><bold>Hemostasis
                                            </bold><bold><italic>Reactome</italic></bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>390</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>1</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>3</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>2</bold></td>
                                <td align="left" colspan="1" rowspan="1"><bold>0</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Rho GTPase cycle <italic>Reactome</italic></td>
                                <td align="left" colspan="1" rowspan="1">265</td>
                                <td align="left" colspan="1" rowspan="1">0</td>
                                <td align="left" colspan="1" rowspan="1">4</td>
                                <td align="left" colspan="1" rowspan="1">4</td>
                                <td align="left" colspan="1" rowspan="1">N/A</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">lck and fyn tyrosine kinases in initiation of tcr
                                    activation <italic>BioCarta</italic></td>
                                <td align="left" colspan="1" rowspan="1">18</td>
                                <td align="left" colspan="1" rowspan="1">0</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">N/A</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">AKT phosphorylates targets in the nucleus
                                        <italic>Reactome</italic></td>
                                <td align="left" colspan="1" rowspan="1">31</td>
                                <td align="left" colspan="1" rowspan="1">0</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">N/A</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">TCR signaling in naïve CD8+ T cells
                                        <italic>PID</italic></td>
                                <td align="left" colspan="1" rowspan="1">107</td>
                                <td align="left" colspan="1" rowspan="1">0</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">N/A</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">TCR <italic>NetPath</italic></td>
                                <td align="left" colspan="1" rowspan="1">267</td>
                                <td align="left" colspan="1" rowspan="1">0</td>
                                <td align="left" colspan="1" rowspan="1">4</td>
                                <td align="left" colspan="1" rowspan="1">4</td>
                                <td align="left" colspan="1" rowspan="1">N/A</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">BCR <italic>NetPath</italic></td>
                                <td align="left" colspan="1" rowspan="1">316</td>
                                <td align="left" colspan="1" rowspan="1">0</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">N/A</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Immunoregulatory interactions between a Lymphoid
                                    and a non-Lymphoid cell <italic>Reactome</italic></td>
                                <td align="left" colspan="1" rowspan="1">138</td>
                                <td align="left" colspan="1" rowspan="1">0</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">N/A</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">amb2 Integrin signaling <italic>PID</italic></td>
                                <td align="left" colspan="1" rowspan="1">98</td>
                                <td align="left" colspan="1" rowspan="1">0</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">N/A</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Apoptotic dna-fragmentation and tissue homeostasis
                                        <italic>BioCarta</italic></td>
                                <td align="left" colspan="1" rowspan="1">17</td>
                                <td align="left" colspan="1" rowspan="1">0</td>
                                <td align="left" colspan="1" rowspan="1">4</td>
                                <td align="left" colspan="1" rowspan="1">4</td>
                                <td align="left" colspan="1" rowspan="1">N/A</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Apoptotic cleavage of cell adhesion proteins
                                        <italic>Reactome</italic></td>
                                <td align="left" colspan="1" rowspan="1">16</td>
                                <td align="left" colspan="1" rowspan="1">0</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">N/A</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Notch receptor binds with a ligand
                                        <italic>Reactome</italic></td>
                                <td align="left" colspan="1" rowspan="1">20</td>
                                <td align="left" colspan="1" rowspan="1">0</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">N/A</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Receptor-ligand binding initiates the second
                                    proteolytic cleavage of Notch receptor
                                    <italic>Reactome</italic></td>
                                <td align="left" colspan="1" rowspan="1">22</td>
                                <td align="left" colspan="1" rowspan="1">0</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">3</td>
                                <td align="left" colspan="1" rowspan="1">N/A</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Integrin cell surface interactions
                                        <italic>Reactome</italic></td>
                                <td align="left" colspan="1" rowspan="1">171</td>
                                <td align="left" colspan="1" rowspan="1">0</td>
                                <td align="left" colspan="1" rowspan="1">4</td>
                                <td align="left" colspan="1" rowspan="1">4</td>
                                <td align="left" colspan="1" rowspan="1">N.A</td>
                            </tr>
                        </tbody>
                    </table></alternatives><table-wrap-foot>
                        <fn id="nt102">
                            <label/>
                            <p>Pathways shown are those significantly over-represented in at least 3
                                drug lists for the inter-omic analysis. N/A indicates no quantified
                                metabolites were present in the pathway. Rows shown in bold are
                                those where the inter-omic analysis means that the pathway is
                                significantly associated with chemosensitivity to more drugs than
                                the individual analyses combined. The pathways are split into two
                                classes, metabolic and non-metabolic and then ordered so that the
                                pathways with improved detection in the inter-omic analysis are at
                                the top of the table.</p>
                        </fn>
                    </table-wrap-foot></table-wrap>
                <p>The added value of the inter-omic OR analysis prior to consensus phenotype
                    integration can be more clearly discerned at the individual pathway level. <xref ref-type="fig" rid="pcbi-1001113-g003">Figure 3</xref> is a network
                    representation of the base excision repair (BER) pathway from Reactome and
                    depicts both the detected entities and the drugs with which each detected entity
                    is associated. While the majority of entities were significantly associated to
                    the effect of at least one of the four platinum agents, there was significant
                    variation in the pattern of association and no gene or metabolite was
                    significantly associated to all four treatments. Accordingly the pathway was
                    only significantly associated to tetraplatin and iproplatin sensitivity using
                    the transcriptome data alone, and to carboplatin and cisplatin sensitivity using
                    the metabolite data in isolation. Using the joint OR analysis the BER pathway
                    was significantly associated to the sensitivity to all four platinum compounds
                        (<xref ref-type="table" rid="pcbi-1001113-t002">Table 2</xref>) and the
                    evidence for association with each drug was increased, due to the added
                    information from the alternative data type. Of the 12 pathways for which
                    inter-omic OR analysis improved the consensus between the drugs, 10 refer to
                    metabolic processes.</p>
                <fig id="pcbi-1001113-g003" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pcbi.1001113.g003</object-id>
                    <label>Figure 3</label>
                    <caption>
                        <title>Base Excision Repair Pathway (Reactome).</title>
                        <p>The Pathway diagram was generated using ConsensusPathDB <xref ref-type="bibr" rid="pcbi.1001113-Kamburov1">[20]</xref>.
                            All quantified metabolites and transcripts are marked and the drugs with
                            which they appeared associated are shown. A solid line indicates a
                            substrate or product (or protein participating in a protein complex) and
                            a dotted line shows an enzymatic link.</p>
                    </caption>
                    <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001113.g003" xlink:type="simple"/>
                </fig>
                <p>In order to validate and to test the generalisability of our findings we then
                    examined GI<sub>50</sub> data from a test compound, diaminocyclohexyl-Pt(II).
                    After conducting the same inter-omic OR analysis as described previously, we
                    observed that the effects of this compound on the NCI60 panel was associated
                    with 5 of the 6 pathways common to all 4 other platinum drugs along with a
                    further 12 pathways from <xref ref-type="table" rid="pcbi-1001113-t002">Table
                        2</xref> and 90% (220/245) of the pathways associated with
                    diaminocyclohexyl-Pt(II) were Associated with at least one of the other platinum
                    drugs. In particular there were 138/152 pathways commonly associated between
                    diaminocyclohexyl-Pt(II), iproplatin and tetraplatin sensitivity. Since OR
                    analysis makes no distinction between positive and negative molecule/sensitivity
                    correlations, we also examined the direction of associations between the
                    metabolites detected in the consensus pathways and the GI<sub>50</sub> of all
                    platinum drugs (<xref ref-type="table" rid="pcbi-1001113-t003">Table 3</xref>).
                    In total, a panel of 22 metabolites were associated with the consensus metabolic
                    pathways from analysis of the four training compounds. While there was variation
                    in the metabolites associated with specific treatments, where a significant
                    association was observed the direction of correlation was consistent across the
                    training set. The GI<sub>50</sub> values of our test compound,
                    diaminocyclohexyl-Pt(II), was significantly correlated to 19/22 metabolites in
                    this panel, with complete consistency in the direction of association with the
                    training set data.</p>
                <table-wrap id="pcbi-1001113-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1001113.t003</object-id><label>Table 3</label><caption>
                        <title>Metabolites involved in the pathways from <xref ref-type="table" rid="pcbi-1001113-t002">Table 2</xref>, showing the direction of
                            association (if above the FDR cutoff) and r, the correlation coefficient
                            to the −log(GI50) values.</title>
                    </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pcbi-1001113-t003-3" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001113.t003" xlink:type="simple"/><table>
                        <colgroup span="1">
                            <col align="left" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                        </colgroup>
                        <thead>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Carboplatin</td>
                                <td align="left" colspan="1" rowspan="1">Cisplatin</td>
                                <td align="left" colspan="1" rowspan="1">Iproplatin</td>
                                <td align="left" colspan="1" rowspan="1">Tetraplatin</td>
                                <td align="left" colspan="1" rowspan="1">Diaminocyclohexyl-Pt II</td>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">2-oxoglutarate</td>
                                <td align="left" colspan="1" rowspan="1">0.18</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.26</td>
                                <td align="left" colspan="1" rowspan="1">0.20</td>
                                <td align="left" colspan="1" rowspan="1">0.12</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.16</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Adenine</td>
                                <td align="left" colspan="1" rowspan="1">0.01</td>
                                <td align="left" colspan="1" rowspan="1">−0.01</td>
                                <td align="left" colspan="1" rowspan="1">0.13</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.21</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.15</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">β-alanine</td>
                                <td align="left" colspan="1" rowspan="1">−0.13</td>
                                <td align="left" colspan="1" rowspan="1">−0.04</td>
                                <td align="left" colspan="1" rowspan="1">0.05</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.28</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.23</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Citrate</td>
                                <td align="left" colspan="1" rowspan="1">0.00</td>
                                <td align="left" colspan="1" rowspan="1">0.01</td>
                                <td align="left" colspan="1" rowspan="1">0.23</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.21</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.19</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">CMP</td>
                                <td align="left" colspan="1" rowspan="1">−0.04</td>
                                <td align="left" colspan="1" rowspan="1">−0.04</td>
                                <td align="left" colspan="1" rowspan="1">0.15</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.22</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.21</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">dUTP</td>
                                <td align="left" colspan="1" rowspan="1">0.20</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.25</td>
                                <td align="left" colspan="1" rowspan="1">0.20</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.24</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.25</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">L-glutamate</td>
                                <td align="left" colspan="1" rowspan="1">0.00</td>
                                <td align="left" colspan="1" rowspan="1">0.09</td>
                                <td align="left" colspan="1" rowspan="1">0.02</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.23</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.22</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Phosphoenol-pyruvate</td>
                                <td align="left" colspan="1" rowspan="1">0.00</td>
                                <td align="left" colspan="1" rowspan="1">0.09</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.26</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.33</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.30</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">S-adenosyl-L-methionine</td>
                                <td align="left" colspan="1" rowspan="1">0.02</td>
                                <td align="left" colspan="1" rowspan="1">−0.01</td>
                                <td align="left" colspan="1" rowspan="1">0.20</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.27</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.20</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Taurine</td>
                                <td align="left" colspan="1" rowspan="1">−0.14</td>
                                <td align="left" colspan="1" rowspan="1">−0.03</td>
                                <td align="left" colspan="1" rowspan="1">0.11</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.45</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↑</bold> 0.35</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Cholesterol</td>
                                <td align="left" colspan="1" rowspan="1">−0.16</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.25</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.35</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.37</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.38</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Deoxyuridine</td>
                                <td align="left" colspan="1" rowspan="1">0.03</td>
                                <td align="left" colspan="1" rowspan="1">0.02</td>
                                <td align="left" colspan="1" rowspan="1">−0.02</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.21</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.18</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Glycerol</td>
                                <td align="left" colspan="1" rowspan="1">−0.21</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.27</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.43</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.38</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.36</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Guanine</td>
                                <td align="left" colspan="1" rowspan="1">−0.02</td>
                                <td align="left" colspan="1" rowspan="1">−0.04</td>
                                <td align="left" colspan="1" rowspan="1">−0.15</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.20</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.18</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Guanosine</td>
                                <td align="left" colspan="1" rowspan="1">−0.06</td>
                                <td align="left" colspan="1" rowspan="1">−0.16</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.30</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.24</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.30</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Hexadecanoic Acid</td>
                                <td align="left" colspan="1" rowspan="1">0.03</td>
                                <td align="left" colspan="1" rowspan="1">−0.09</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.26</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.22</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.27</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Hypoxanthine</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.36</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.36</td>
                                <td align="left" colspan="1" rowspan="1">−0.13</td>
                                <td align="left" colspan="1" rowspan="1">−0.05</td>
                                <td align="left" colspan="1" rowspan="1">−0.04</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Inosine</td>
                                <td align="left" colspan="1" rowspan="1">−0.21</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.25</td>
                                <td align="left" colspan="1" rowspan="1">−0.07</td>
                                <td align="left" colspan="1" rowspan="1">−0.05</td>
                                <td align="left" colspan="1" rowspan="1">−0.10</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Uracil</td>
                                <td align="left" colspan="1" rowspan="1">−0.19</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.25</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.28</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.19</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.21</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Urea</td>
                                <td align="left" colspan="1" rowspan="1">−0.14</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.25</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.31</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.36</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.37</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Uridine</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.38</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.34</td>
                                <td align="left" colspan="1" rowspan="1">−0.17</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.18</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.20</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Xanthine</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.32</td>
                                <td align="left" colspan="1" rowspan="1"><bold>↓</bold> −0.25</td>
                                <td align="left" colspan="1" rowspan="1">−0.13</td>
                                <td align="left" colspan="1" rowspan="1">−0.07</td>
                                <td align="left" colspan="1" rowspan="1">−0.02</td>
                            </tr>
                        </tbody>
                    </table></alternatives></table-wrap>
            </sec>
            <sec id="s2c">
                <title>Global analysis of chemosensitivity pathways</title>
                <p>To explore more broadly the relationships between chemosensitivity and biological
                    pathways across a range of agents, and to ascertain the specificity of the
                    consensus phenotype analysis for platinum sensitivity pathways, inter-omic OR
                    analysis was performed using GI<sub>50</sub> data for all 118 compounds
                    available within the NCI 60 dataset. In total 1262 pathways were significantly
                    associated with the drug sensitivity of at least one compound, while 82
                    compounds gave at least one significant pathway. <xref ref-type="fig" rid="pcbi-1001113-g004">Figure 4</xref> shows the clustered heat-map of the
                    binary association matrix in which each element is set to one if a pathway is
                    significantly associated with sensitivity to a given drug and zero otherwise
                    (see <xref ref-type="supplementary-material" rid="pcbi.1001113.s002">Table
                        S2</xref>). Significant clustering of the drugs according to mode of action
                    is visible. For example the dihhryofolate reductase inhibitor methotrexate
                    co-clustered with related compounds aminopterin, trimetrexate, and
                    Baker's-soluble-antifolate (triazinate) (<xref ref-type="fig" rid="pcbi-1001113-g004">Figure 4</xref>, blue asterisks); the sensitivities
                    to all four compounds were associated with 91 common pathways. While one might
                    expect structural analogues such as these to produce a similar pattern of
                    sensitivity and hence similar pathway associations, structurally unrelated
                    compounds that share a common molecular target also co-clustered in certain
                    instances. One interesting observation was the similarity in pathway
                    association, reflected by common membership of a cluster, of several structural
                    analogues, the anthracycline-based compounds, (doxorubicin, zorubicin,
                    danorubicin hydrochloride and deoxydoxorubicin) with the podophyllotoxin-based
                    etoposide and teniposide (<xref ref-type="fig" rid="pcbi-1001113-g004">Figure
                        4</xref>, green asterisks). The four anthracyclines in the cluster share a
                    large proportion of associated pathways: 63 of the 401 pathways associated with
                    any of the anthracyclines are commonly associated to the effect of all four
                    compounds, and of these, 60 are also associated to the chemosensitivity to
                    either teniposide or etoposide. Etoposide and its derivatives directly inhibit
                    topoisomerase II activity, followed by induction of DNA strand breaks and
                    selective cytotoxicity in tumour cells <xref ref-type="bibr" rid="pcbi.1001113-Hande1">[25]</xref> whereas anthracyclines
                    intercalate DNA, indirectly inhibiting the progression of topoisomerase II and
                    blocking replication <xref ref-type="bibr" rid="pcbi.1001113-Minotti1">[26]</xref>. Thus, the inter-omic pathway analysis is apparently
                    able to associate chemosensitivity phenotypes on the basis of a common
                    pathophysiological link independent of whether the key molecular targets are
                    affected directly, or indirectly by an upstream process.</p>
                <fig id="pcbi-1001113-g004" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pcbi.1001113.g004</object-id>
                    <label>Figure 4</label>
                    <caption>
                        <title>Clustering drugs according to the pathways significantly correlated
                            to sensitivity.</title>
                        <p>Red and blue indicates a pathway which is or is not significant in the
                            inter-omic analysis. A significance level of p&lt;0.05 was used for each
                            pathway. Clustering was performed using complete linkage and the Hamming
                            distance metric. Pathways not associated with any drug have been omitted
                            from the figure. Red asterisks indicate platinum drugs, blue asterisks
                            indicate antifolates and green asterisks indicate anthracycline-based
                            drugs.</p>
                    </caption>
                    <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001113.g004" xlink:type="simple"/>
                </fig>
                <p>While such mechanistic relationships were readily observable, the most prominent
                    division between the compounds, visible as the two largest clusters in <xref ref-type="fig" rid="pcbi-1001113-g004">Figure 4</xref>, appeared to be
                    separating on the overall frequency of pathways associated with
                    chemosensitivity, with the top cluster in the diagram possessing on average 2.95
                    times the number of positive associations of the lower cluster. While each of
                    the five platinum compounds in the dataset were most similar in pathway
                    associations to another platinum compound, they were separated across the two
                    largest clusters with cisplatin and carboplatin forming one group and
                    tetraplatin, iroplatin and diaminocyclohexyl-Pt II another. This separation
                    agreed with the low numbers of common chemosensitivity pathways between members
                    of these two groups in earlier analyses (<xref ref-type="fig" rid="pcbi-1001113-g002">Figure 2</xref>). Thus, the clustering structure did
                    not describe associations common across the platinum compounds, illustrating the
                    difficulty of using clustering approaches alone to identify pathways that may
                    determine class-specific chemosensitivity and the advantages of the consensus
                    phenotype approach.</p>
                <p>To assess the specificity of the identified consensus platinum-sensitivity
                    pathways we compared these to the most frequently associated pathways in the
                    global inter-omic OR analysis (<xref ref-type="supplementary-material" rid="pcbi.1001113.s002">Table S2</xref>). Of the 54 (top 50 including ties)
                    most frequently associated pathways (<xref ref-type="supplementary-material" rid="pcbi.1001113.s003">Table S3</xref>), just seven intersect with pathways
                    identified by consensus phenotype integration, mostly related to
                    immunoregulatory processes (“T-cell receptor” – Netpath;
                    “B-Cell receptor” – Netpath; “Rho GTPase cycle”
                    – Reactome; “lCK and FYN tyrosine kinases in initiation of TCR
                    activation” – BioCarta; “AMB2 integrin signalling”
                    – PID; “Immunoregulatory interactions between a Lymphoid and a
                    non-Lymphoid cell” – Reactome; and “TCR signalling in naive
                    CD8 T cells” – PID). Hence the remaining 23/30 consensus
                    platinum-sensitivity pathways, dominated by metabolic processes, are not
                    associated with sensitivity to a wide range of chemotherapeutic agents and are
                    more likely to be specific to platinum sensitivity.</p>
            </sec>
        </sec>
        <sec id="s3">
            <title>Discussion</title>
            <p>Our results show that an inter-omic, consensus phenotype approach to integration of
                molecular profiles can reveal a cellular metabolic phenotype robustly associated
                with platinum chemosensitivity across the NCI-60 cell line panel. Many of the
                specific aspects of this phenotype are consistent with the perturbations described
                across many studies of tumour cell metabolism, and several of these have been
                associated with the development, or likely acquisition, of drug resistance
                phenotypes. The classic hallmark of tumour cell metabolism is the Warburg effect: an
                increase in glucose uptake and glycolysis to lactate even in normal oxygen
                conditions. In addition to the Warburg effect tumour cells are frequently reported
                as exhibiting higher rates of glutaminolysis, fatty acid and lipid metabolism, and
                nucleotide synthesis <xref ref-type="bibr" rid="pcbi.1001113-Hsu1">[27]</xref>. Our observations from the NCI-60 molecular profiles
                suggest a positive correlation between all of these phenotypes and platinum
                chemosensitivity.</p>
            <p><xref ref-type="fig" rid="pcbi-1001113-g005">Figure 5</xref> summarises some of the
                key correlations observed between gene transcription, metabolite levels and platinum
                sensitivity from the consensus pathways indicated by our analysis. The relatively
                higher levels of citrate and phosphoenolpyruvate (PEP), observed in more sensitive
                cell lines (<xref ref-type="fig" rid="pcbi-1001113-g005">Figure 5A</xref>), are
                consistent with low TCA cycle activity (via product inhibition) and increased
                diversion of glycolytic intermediates into anabolic pathways such as the pentose
                phosphate which feeds nucleotide synthesis <xref ref-type="bibr" rid="pcbi.1001113-Mazurek1">[28]</xref>. Under these conditions tumour
                cells increase the uptake of glutamine and its conversion to oxaloacetate via
                glutamate and 2-oxoglutarate (2-OG) in order to replace TCA cycle intermediates and
                NADPH <xref ref-type="bibr" rid="pcbi.1001113-DeBerardinis1">[29]</xref>.
                Both glutamate and 2-OG levels were also higher in more sensitive cell lines. Thus
                more ‘Warburg–like’ cells appear more sensitive to platinum
                treatment than less metabolically transformed lines. The selection of TCA cycle and
                pyruvate metabolism as a sensitivity pathway in our analysis is likely to reflect
                these associations.</p>
            <fig id="pcbi-1001113-g005" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pcbi.1001113.g005</object-id>
                <label>Figure 5</label>
                <caption>
                    <title>Processes associated with platinum sensitivity.</title>
                    <p>Three processes associated with platinum sensitivity, the arrows indicate the
                        direction of correlation to the −log(GI50) values for that gene or
                        metabolite. <bold>A</bold> Energy metabolism. <bold>B</bold> Nucleotide
                            <italic>de novo</italic> synthesis and salvage. <bold>C</bold> Lipid
                        uptake.</p>
                </caption>
                <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001113.g005" xlink:type="simple"/>
            </fig>
            <p>The dependency of tumour cells on glycolysis for synthetic intermediates could be
                exploited in platinum chemotherapy; for example the clinically-relevant glycolysis
                inhibitor 2-deoxy-glucose (2-DG) has been shown to enhance cisplatin cytotoxicity in
                head and neck cancer cells <xref ref-type="bibr" rid="pcbi.1001113-Simons1">[30]</xref>. Interestingly, this synergy appeared to be mediated in
                part via oxidative stress, a process that would lead to DNA lesions (e.g.
                8-oxo-2′-deoxyguanosine) requiring base excision repair (BER) which was one of
                the key consensus sensitivity pathways selected by our analysis (<xref ref-type="fig" rid="pcbi-1001113-g003">Figure 3</xref>). While it is clear that
                nucleotide excision repair (NER) capacity is linked to cisplatin resistance <xref ref-type="bibr" rid="pcbi.1001113-Kartalou1">[31]</xref>, <xref ref-type="bibr" rid="pcbi.1001113-Siddik1">[32]</xref>, <xref ref-type="bibr" rid="pcbi.1001113-Wernyj1">[33]</xref>; it is becoming
                evident that BER is also important in the effect of cisplatin derived drugs <xref ref-type="bibr" rid="pcbi.1001113-Preston1">[34]</xref>. Cross-linking
                of DNA via platinum derived drugs can increase the production of free radicals by
                disrupting the cellular redox balance <xref ref-type="bibr" rid="pcbi.1001113-Goodisman1">[35]</xref>. We suggest that the
                association of the BER pathway with four platinum drugs observed in the present
                study is related to increased ROS production and not adduct formation (repaired by
                NER). Intracellular levels of ROS seem vital to the cytotoxic effect of the platinum
                derived drugs, further evidenced by the fact that oxaliplatin (a later generation of
                Pt drug) is highly cytotoxic but forms less platinum-DNA adducts compared to equal
                amounts of cisplatin <xref ref-type="bibr" rid="pcbi.1001113-Goodisman1">[35]</xref>.</p>
            <p>A particularly high degree of coordination between gene transcript and metabolite
                levels was observed in nucleotide metabolism, revealing a robust association between
                increased nucleotide synthesis, both <italic>de novo</italic> and via recovery of
                catabolic intermediates, and tumour cell Pt sensitivity (<xref ref-type="fig" rid="pcbi-1001113-g005">Figure 5B</xref>). For example, in the <italic>de
                    novo</italic> pathway, we observed a positive correlation between levels of dUTP
                (a precursor to dTMP), expression of dUTP pyrophosphatase (DUT
                r = 0.38), expression of thymidylate synthase (TYSY
                r = 0.27) and platinum sensitivity. dUTP has to be hydrolysed
                to dUMP by DUT to prevent the incorporation of uracils into DNA and suppression of
                DUT has been shown to sensitize cells to other chemotherapeutics such as pyrimidine
                anti-metabolites <xref ref-type="bibr" rid="pcbi.1001113-Koehler1">[36]</xref>.</p>
            <p>Increased expression of nucleotide salvage pathway enzymes (e.g. uracil
                phosphoribosyl transferase or UPP (r = 0.20),
                hypoxanthine-guanine phosphoribosyl transferase or HPRT,
                r = 0.27) in sensitive cell lines was accompanied by decreases
                in several intermediates of purine and pyrimidine catabolism (namely guanine,
                guanosine, hypoxanthine, inosine, uracil, uridine and urea) and increase in CMP, the
                nucleotide product of HPRT. Kowalski et al. <xref ref-type="bibr" rid="pcbi.1001113-Kowalski1">[37]</xref> have shown clear links
                between inactivation of salvage pathway enzymes such as HGPRT or loss of feedback
                inhibition to AMP and GMP <italic>de novo</italic> synthesis and cisplatin
                resistance in yeast. Interestingly in the same study the addition of low
                concentrations of extracellular purines also abolished cisplatin cytotoxicity; thus
                the metabolome may have a causal influence on platinum sensitivity and not just
                represent epiphenomena that is a passive consequence of aberrant cell division.</p>
            <p>Our pathway analysis also predicts that lipid metabolism has a direct impact on
                chemosensitivity. We observed lower cholesterol, glycerol, and hexadecanoic acid
                (palmitate) in more sensitive cell lines, together with negative correlations
                between expression of apolipoprotein E (APOE; mean
                R = −0.21), LDL receptor (LDLR; mean
                R = −0.27) and platinum sensitivity (<xref ref-type="fig" rid="pcbi-1001113-g005">Figure 5C</xref>). All these observations are consistent
                with a hypothesis that increased uptake of lipoproteins and constituent
                triglycerides, fatty acids and cholesterols can confer resistance to platinum, a
                phenomenon previously shown in drug resistant leukemic cell lines <xref ref-type="bibr" rid="pcbi.1001113-Tatidis1">[38]</xref>. A related
                pathway highlighted as associated with sensitivity was phosphatidylcholine
                biosynthesis. We observed a positive correlation between choline kinase (CK,
                r = −0.28, correlation to −log(GI50)) expression
                and resistance to platinum. Recent work by Shah et al. <xref ref-type="bibr" rid="pcbi.1001113-Shah1">[39]</xref> in breast cancer cells have shown
                that CK regulates pro-survival MAPk and PI3K/Akt signaling via phosphatidic acid,
                and that overexpression leads to drug resistance.</p>
            <p>While previous pathway analysis was conducted on gene expression profiles alone from
                the NCI60 dataset <xref ref-type="bibr" rid="pcbi.1001113-Riedel1">[40]</xref>, the use of correlation analysis and the combination of
                metabolite and gene transcription measures in our study provides an unprecedented
                level of detail into the contribution of metabolic pathways to drug sensitivity.
                Using gene set enrichment analysis (GSEA), Reidel et al. <xref ref-type="bibr" rid="pcbi.1001113-Riedel1">[40]</xref> suggested that, in addition to
                a number of cell signaling and survival networks, methionine metabolism may
                contribute to chemotherapeutic resistance to multiple agents, while fatty acid and
                β-alanine metabolism were specifically associated with platinum-resistance. In
                the context of fatty acid metabolism we show here that lipid uptake and processing
                may in fact be the driving factor in this association. It is also interesting to
                note that although we did not observe over-representation of β-alanine and
                methionine metabolic pathways, both β-alanine and S-adenosylmethionine levels
                were significantly positively correlated to platinum sensitivity, adding functional
                evidence in support of these earlier findings.</p>
            <p>At present, our study is one of very few that presents a strategy for simultaneous
                interpretation of gene expression data, metabolic profiles and physiological
                endpoints using biological pathway analysis, and has several advantages over other
                approaches. Multivariate analysis using pattern recognition algorithms such as PCA,
                    <xref ref-type="bibr" rid="pcbi.1001113-Heijne2">[41]</xref>, PLS
                    <xref ref-type="bibr" rid="pcbi.1001113-Rantalainen2">[42]</xref> and
                Kohonen Networks (Self-Organising maps) <xref ref-type="bibr" rid="pcbi.1001113-Hirai2">[43]</xref>, have been shown to be useful in
                revealing novel associations between “-omics” datasets, but fail to take
                into account prior biological knowledge relevant to the phenomenon at hand - a
                feature which is clearly present in pathway-based techniques. Gene and metabolite
                coregulation at the pathway level has been previously studied using OR analysis
                    <xref ref-type="bibr" rid="pcbi.1001113-Bradley1">[44]</xref>, <xref ref-type="bibr" rid="pcbi.1001113-Gibon1">[45]</xref>. Transcripts
                significantly correlated to metabolite levels were examined for over-representation
                of Gene Ontology terms <xref ref-type="bibr" rid="pcbi.1001113-Ashburner1">[46]</xref> or pathways (defined by MapMan BINS). Bradley and
                Gibons' work reveals a degree of coordination present between transcriptional
                and metabolic measurements at a pathway level, a necessary prerequisite for our
                approach to be successful. Importantly none of these examples use a function
                physiological endpoint (cytotoxicity) as driver in pathway selection, leading to a
                consensus phenotype description of the phenomenon of interest. We show here that
                such an approach is critical in reducing false positive selection of pathways.</p>
            <p>All OR techniques share the limitation that they rely on a database containing
                pre-defined pathways, and therefore cannot identify novel pathways or functional
                modules. In this work we have tried to overcome this limitation somewhat through
                deconstructing the pathways which were significantly associated and then
                functionally interpreting the elements of the pathways which showed significant
                associations (<xref ref-type="fig" rid="pcbi-1001113-g005">Figure 5</xref>).
                However, even this requires that the elements of the process are sufficiently
                grouped in existing pathways to allow for those pathways to be significantly
                associated.</p>
            <p>Ultimately, a systems biology approach, such as the inter-omic pathway analysis
                presented in our study, could assist the development of anti-resistance
                chemotherapeutic strategies, and better individualization of treatment, i.e.
                personalized medicine. Using gene expression models (GEMs) based on cytotoxicity in
                the NCI-60 panel, Williams et al. <xref ref-type="bibr" rid="pcbi.1001113-Williams1">[47]</xref> were able to stratify tumour response and/or patient
                survival in seven independent cohorts of patients with breast, bladder and ovarian
                cancer. Crucially, the <italic>in vitro</italic> derived GEMs outperformed those
                derived directly from <italic>in vivo</italic> data. Recently it has also been shown
                that pre-treatment metabolic profiles can be used to predict the metabolic fate or
                effect of drugs in rodents <xref ref-type="bibr" rid="pcbi.1001113-Clayton1">[48]</xref>, healthy humans <xref ref-type="bibr" rid="pcbi.1001113-Clayton2">[49]</xref>, <xref ref-type="bibr" rid="pcbi.1001113-Winnike1">[50]</xref> and breast cancer patients
                    <xref ref-type="bibr" rid="pcbi.1001113-Keun1">[51]</xref>. Given that
                the metabolic phenotype of cancer is already the basis of imaging techniques such as
                FDG-PET that are currently used to detect early responses to therapy, there is
                potentially great value in combing such pharmaco-metabonomic studies with other
                characterization of the patient or tumour genome and it is our belief that the
                integration of molecular profile data yields more than the sum of its parts. It
                remains to be seen if the combination of “-omics” data provides a
                competitive advantage over targeted biomarker studies for prognosis and prediction
                of drug response in oncology. It remains to be seen if the combination of
                “-omics” data provides a competitive advantage over targeted biomarker
                studies for prognosis and prediction of drug response in oncology. Several major
                challenges to such approaches and translation from in vitro studies, in particular
                tumour heterogeneity, require further study. However, irrespective of biomarker
                development, the knowledge that chemotherapeutic sensitivity is in part determined
                by the metabolic phenotype suggests that metabolic enzymes may be potential targets
                in oncology for both drug naive and chemoresistant patients.</p>
        </sec>
        <sec id="s4" sec-type="methods">
            <title>Methods</title>
            <sec id="s4a">
                <title>NCI60 and pathway data</title>
                <p>The NCI60 data was downloaded from <ext-link ext-link-type="uri" xlink:href="http://dtp.nci.nih.gov/mtargets/download.html" xlink:type="simple">http://dtp.nci.nih.gov/mtargets/download.html</ext-link> on 27th August
                    2008. For this work three datasets were used: metabolite levels, gene expression
                    levels and drug sensitivities. The metabolite data consists of measurements of
                    352 metabolites, 154 identified, across 58 cell lines, performed by Metabolon
                    Inc. <xref ref-type="bibr" rid="pcbi.1001113-Sreekumar1">[52]</xref>.
                    The transcriptomics data was obtained using the U133 Affymetrix chip by
                    Genelogic <xref ref-type="bibr" rid="pcbi.1001113-Shankavaram1">[17]</xref>. 44928 probesets were measured, equating to 17150
                    genes mapping to distinct UniProt identifiers, measured across the same 58 cell
                    lines. The drug resistance data was selected from the 118 ‘mechanism of
                    action’ drugs data <xref ref-type="bibr" rid="pcbi.1001113-Scherf1">[15]</xref>, <xref ref-type="bibr" rid="pcbi.1001113-Bussey1">[16]</xref>. Each compound was profiled in between 2 and 1176
                    independent experiments in a 48-hour sulforhodamine B assay. The values used are
                    the −log(GI<sub>50</sub>), where GI<sub>50</sub> is the dosage of the drug
                    which inhibits the growth of the cells by 50%. . GI<sub>50</sub> values
                    were averaged across the replicates for each cell line, thus increasing the
                    robustness of the primary phenotypic endpoint.</p>
                <p>Pathways were derived from the ConsensusPathDB <xref ref-type="bibr" rid="pcbi.1001113-Kamburov1">[20]</xref> which assimilates
                    pathways from a range of public databases (see <xref ref-type="sec" rid="s2">Results</xref>). Gene IDs are mapped to UniProt <xref ref-type="bibr" rid="pcbi.1001113-Apweiler1">[53]</xref> protein IDs. For
                    metabolites, where available KEGG <xref ref-type="bibr" rid="pcbi.1001113-Kanehisa1">[21]</xref> compound IDs were used,
                    else, ChEBI <xref ref-type="bibr" rid="pcbi.1001113-Degtyarenko1">[54]</xref> IDs were used.</p>
            </sec>
            <sec id="s4b">
                <title>Construction of gene/metabolite lists and over-representation
                    analysis</title>
                <p>Pearson correlations were calculated between all transcript/metabolite levels and
                        −log(GI<sub>50</sub>) values for each drug. Transcripts/metabolites
                    significant below a false discovery rate threshold of 60% were retained
                    in each test set for OR analysis. Each UniProt identifier in the ConsensusPathDB
                    pathways can be mapped to zero or more gene identifiers on the U133 chip. The
                    background estimate (m in equation 1) for OR analysis was adjusted to reflect
                    the following: 1) Where ConsensusPathDB proteins could not be mapped to any gene
                    identifiers, these were ignored; and 2) where ConsensusPathDB proteins mapped to
                    multiple probesets measuring genes in the transcript data, the number of
                    probesets was used. In addition, several metabolites, often referred to as
                    “currency metabolites”, which appear in many pathways and do not
                    provide specificity were removed before analysis. The currency metabolites
                    removed were phosphate, diphosphate and NADP+. Thus, given the
                    transcriptomic and metabolomic data, an “effective size”,
                            <italic>N<sub>i</sub></italic>, could be defined for each pathway,
                        <italic>I</italic>, in terms of genes and metabolites, The effective pathway
                    size may be larger or smaller than the actual number of proteins/metabolites in
                    the pathway. Pathway significance was calculated using the hypergeometric
                            distribution,<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001113.e001" xlink:type="simple"/><label>(1)</label></disp-formula>where K is the number of genes or
                    metabolites associated with the drug and k<sub>i</sub> is the number of genes or
                    metabolites from the pathway. P&lt;0.05 was used as the criterion defining
                    significance of pathway enrichment.</p>
            </sec>
            <sec id="s4c">
                <title>Joint transcript and metabolite analysis</title>
                <p>We used the pathway p-values <italic>p<sub>i</sub></italic> from the individual
                    analyses to combine the data. If there were no transcripts or no metabolites
                    measured for pathway <italic>i</italic>, we set
                    <italic>p<sub>i</sub></italic> = 1 for that data type.
                    Since the transcript/metabolite data were generated from separate experiments.
                    We thus assumed independence of the pathway associations from the different data
                    sets. We thus computed the joint probability <italic>p<sub>Ji</sub></italic> of
                    association of pathway <italic>i</italic> with the drug sensitivity phenotype as
                            <italic>p<sub>Ji</sub></italic> = <italic>p<sub>Gi</sub>
                            p<sub>Mi</sub></italic> where <italic>p<sub>Gi</sub></italic> and
                            <italic>p<sub>Mi</sub></italic> denote the probability of association
                    from the individual gene and metabolite data separately.</p>
            </sec>
            <sec id="s4d">
                <title>Null models</title>
                <p>Null model 1 was generated by creating random gene and metabolite lists of
                    matching size to those observed for each of the drugs. Standard OR analysis was
                    then performed and then numbers of overlapping pathways were recorded. 100 sets
                    of random lists were generated and the mean number of pathways common to
                    different numbers of drugs were recorded in <xref ref-type="table" rid="pcbi-1001113-t001">table 1</xref>.</p>
                <p>Null model II assumes that the pathways are selected at random, and so taking the
                    numbers of pathways selected for each drug, the exact probability of a pathway
                    being selected for <italic>n</italic> drugs was calculated. To do this we
                    calculated the probability of a pathway being selected at random from the full
                    list of pathways, given the number of pathways selected. By calculating this for
                    each of the drugs we have.</p>
                <p>Additionally, we examined the added information given by the joint analysis. For
                    each drug the lists of p-values from the metabolite and transcript analyses were
                    randomly permuted 100 times before combination (randomizing the pathway
                    association between the two sets). The number of times in which more pathways
                    were significant (p&lt;0.05) for the permuted lists than in the real data was
                    recorded.</p>
                <p>Cumulative false discovery rates for all models were calculated by dividing the
                    ‘expected’ number of pathways as given by the null model, by the
                    actual (cumulative) number of pathways found in the real data in at least
                        <italic>n</italic> drugs.</p>
            </sec>
        </sec>
        <sec id="s5">
            <title>Supporting Information</title>
            <supplementary-material id="pcbi.1001113.s001" mimetype="application/vnd.ms-excel" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001113.s001" xlink:type="simple">
                <label>Table S1</label>
                <caption>
                    <p>Panels of genes and metabolites that were deemed to be associated with the
                        sensitivity to each drug.</p>
                    <p>(0.57 MB XLS)</p>
                </caption>
            </supplementary-material>
            <supplementary-material id="pcbi.1001113.s002" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001113.s002" xlink:type="simple">
                <label>Table S2</label>
                <caption>
                    <p>The binary table used to produce the heatmap in <xref ref-type="fig" rid="pcbi-1001113-g004">Figure 4</xref>.</p>
                    <p>(0.39 MB XLSX)</p>
                </caption>
            </supplementary-material>
            <supplementary-material id="pcbi.1001113.s003" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001113.s003" xlink:type="simple">
                <label>Table S3</label>
                <caption>
                    <p>The pathways most frequently associated with drugs from the panel.</p>
                    <p>(0.01 MB XLSX)</p>
                </caption>
            </supplementary-material>
            <supplementary-material id="pcbi.1001113.s004" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001113.s004" xlink:type="simple">
                <label>Table S4</label>
                <caption>
                    <p>List of metabolites measured in the NCI60 panel, along with our assigned KEGG
                        IDs.</p>
                    <p>(0.05 MB XLSX)</p>
                </caption>
            </supplementary-material>
        </sec>
    </body>
    <back>
        <ref-list>
            <title>References</title>
            <ref id="pcbi.1001113-Ebbels1">
                <label>1</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Ebbels</surname>
                            <given-names>TMD</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Cavill</surname>
                            <given-names>R</given-names>
                        </name>
                    </person-group>
                    <year>2009</year>
                    <article-title>Bioinformatic methods in NMR-based metabolic
                        profiling.</article-title>
                    <source>Prog Nucl Mag Res Sp</source>
                    <volume>55</volume>
                    <fpage>361</fpage>
                    <lpage>374</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Craig1">
                <label>2</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Craig</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sidaway</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Holmes</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Orton</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Jackson</surname>
                            <given-names>D</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2006</year>
                    <article-title>Systems Toxicology: Integrated Genomic, Proteomic and Metabonomic
                        Analysis of Methapyrilene Induced Hepatotoxicity in the Rat.</article-title>
                    <source>J Proteome Res</source>
                    <volume>5</volume>
                    <fpage>1586</fpage>
                    <lpage>1601</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Hirai1">
                <label>3</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Hirai</surname>
                            <given-names>MY</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Yano</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Goodenowe</surname>
                            <given-names>DB</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kanaya</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kimura</surname>
                            <given-names>T</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2004</year>
                    <article-title>Integration of transcriptomics and metabolomics for understanding
                        of global responses to nutritional stresses in Arabidopsis
                        thaliana.</article-title>
                    <source>Proc Natl Acad Sci USA</source>
                    <volume>101</volume>
                    <fpage>10205</fpage>
                    <lpage>10210</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Heijne1">
                <label>4</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Heijne</surname>
                            <given-names>WHM</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Stierum</surname>
                            <given-names>RH</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Slijper</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>van Bladeren</surname>
                            <given-names>PJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>van Ommen</surname>
                            <given-names>B</given-names>
                        </name>
                    </person-group>
                    <year>2003</year>
                    <article-title>Toxicogenomics of bromobenzene hepatotoxicity: a combined
                        transcriptomics and proteomics approach.</article-title>
                    <source>Biochem Pharmacol</source>
                    <volume>65</volume>
                    <fpage>857</fpage>
                    <lpage>875</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Lanckriet1">
                <label>5</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Lanckriet</surname>
                            <given-names>GR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>De Bie</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Cristianini</surname>
                            <given-names>N</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Jordan</surname>
                            <given-names>MI</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Noble</surname>
                            <given-names>WS</given-names>
                        </name>
                    </person-group>
                    <year>2004</year>
                    <article-title>A statistical framework for genomic data fusion.</article-title>
                    <source>Bioinformatics</source>
                    <volume>20</volume>
                    <fpage>2626</fpage>
                    <lpage>2635</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Rantalainen1">
                <label>6</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Rantalainen</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Cloarec</surname>
                            <given-names>O</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Beckonert</surname>
                            <given-names>O</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Wilson</surname>
                            <given-names>ID</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Jackson</surname>
                            <given-names>D</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2006</year>
                    <article-title>Statistically integrated metabonomic-proteomic studies on a human
                        prostate cancer xenograft model in mice.</article-title>
                    <source>J Proteome Res</source>
                    <volume>5</volume>
                    <fpage>2642</fpage>
                    <lpage>2655</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Joyce1">
                <label>7</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Joyce</surname>
                            <given-names>AR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Palsson</surname>
                            <given-names>BO</given-names>
                        </name>
                    </person-group>
                    <year>2006</year>
                    <article-title>The model organism as a system: integrating ‘omics’
                        data sets.</article-title>
                    <source>Nat Rev Mol Cell Biol</source>
                    <volume>7</volume>
                    <fpage>198</fpage>
                    <lpage>210</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Bylesjo1">
                <label>8</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Bylesjo</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Eriksson</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kusano</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Moritz</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Trygg</surname>
                            <given-names>J</given-names>
                        </name>
                    </person-group>
                    <year>2007</year>
                    <article-title>Data integration in plant biology: the O2PLS method for combined
                        modeling of transcript and metabolite data.</article-title>
                    <source>Plant J</source>
                    <volume>52</volume>
                    <fpage>1181</fpage>
                    <lpage>1191</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Dumas1">
                <label>9</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Dumas</surname>
                            <given-names>ME</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Wilder</surname>
                            <given-names>SP</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bihoreau</surname>
                            <given-names>MT</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Barton</surname>
                            <given-names>RH</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Fearnside</surname>
                            <given-names>JF</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2007</year>
                    <article-title>Direct quantitative trait locus mapping of mammalian metabolic
                        phenotypes in diabetic and normoglycemic rat models.</article-title>
                    <source>Nat Genet</source>
                    <volume>39</volume>
                    <fpage>666</fpage>
                    <lpage>672</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Chuang1">
                <label>10</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Chuang</surname>
                            <given-names>H-Y</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lee</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Liu</surname>
                            <given-names>Y-T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lee</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ideker</surname>
                            <given-names>T</given-names>
                        </name>
                    </person-group>
                    <year>2007</year>
                    <article-title>Network-based classification of breast cancer
                        metastasis.</article-title>
                    <source>Mol Syst Biol</source>
                    <volume>3</volume>
                    <fpage>140</fpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Tavazoie1">
                <label>11</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Tavazoie</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hughes</surname>
                            <given-names>JD</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Campbell</surname>
                            <given-names>MJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Cho</surname>
                            <given-names>RJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Church</surname>
                            <given-names>GM</given-names>
                        </name>
                    </person-group>
                    <year>1999</year>
                    <article-title>Systematic determination of genetic network
                        architecture.</article-title>
                    <source>Nat Genet</source>
                    <volume>22</volume>
                    <fpage>281</fpage>
                    <lpage>285</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Curtis1">
                <label>12</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Curtis</surname>
                            <given-names>RK</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Oresic</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Vidal-Puig</surname>
                            <given-names>A</given-names>
                        </name>
                    </person-group>
                    <year>2005</year>
                    <article-title>Pathways to the analysis of microarray data.</article-title>
                    <source>Trends Biotechnol</source>
                    <volume>23</volume>
                    <fpage>429</fpage>
                    <lpage>435</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Xia1">
                <label>13</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Xia</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Wishart</surname>
                            <given-names>DS</given-names>
                        </name>
                    </person-group>
                    <year>2010</year>
                    <article-title>MSEA: a web-based tool to identify biologically meaningful
                        patterns in quantitative metabolomic data.</article-title>
                    <source>Nucl Acids Res</source>
                    <volume>38</volume>
                    <fpage>W71</fpage>
                    <lpage>77</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Sabatine1">
                <label>14</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Sabatine</surname>
                            <given-names>MS</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Liu</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Morrow</surname>
                            <given-names>DA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Heller</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>McCarroll</surname>
                            <given-names>R</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2005</year>
                    <article-title>Metabolomic Identification of Novel Biomarkers of Myocardial
                        Ischemia.</article-title>
                    <source>Circulation</source>
                    <volume>112</volume>
                    <fpage>3868</fpage>
                    <lpage>3875</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Scherf1">
                <label>15</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Scherf</surname>
                            <given-names>U</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ross</surname>
                            <given-names>DT</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Waltham</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Smith</surname>
                            <given-names>LH</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lee</surname>
                            <given-names>JK</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2000</year>
                    <article-title>A gene expression database for the molecular pharmacology of
                        cancer.</article-title>
                    <source>Nat Genet</source>
                    <volume>24</volume>
                    <fpage>236</fpage>
                    <lpage>244</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Bussey1">
                <label>16</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Bussey</surname>
                            <given-names>KJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Chin</surname>
                            <given-names>K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lababidi</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Reimers</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Reinhold</surname>
                            <given-names>WC</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2006</year>
                    <article-title>Integrating data on DNA copy number with gene expression levels
                        and drug sensitivities in the NCI-60 cell line panel.</article-title>
                    <source>Mol Cancer Ther</source>
                    <volume>5</volume>
                    <fpage>853</fpage>
                    <lpage>867</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Shankavaram1">
                <label>17</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Shankavaram</surname>
                            <given-names>UT</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Reinhold</surname>
                            <given-names>WC</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Nishizuka</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Major</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Morita</surname>
                            <given-names>D</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2007</year>
                    <article-title>Transcript and protein expression profiles of the NCI-60 cancer
                        cell panel: an integromic microarray study.</article-title>
                    <source>Mol Cancer Ther</source>
                    <volume>6</volume>
                    <fpage>820</fpage>
                    <lpage>832</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Holbeck1">
                <label>18</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Holbeck</surname>
                            <given-names>S</given-names>
                        </name>
                    </person-group>
                    <year>2007</year>
                    <article-title>Molecular Target Data.</article-title>
                    <comment>Available: <ext-link ext-link-type="uri" xlink:href="http://dtp.nci.nih.gov/mtargets/download.html" xlink:type="simple">http://dtp.nci.nih.gov/mtargets/download.html</ext-link></comment>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Benjamini1">
                <label>19</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Benjamini</surname>
                            <given-names>Y</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hochberg</surname>
                            <given-names>Y</given-names>
                        </name>
                    </person-group>
                    <year>1995</year>
                    <article-title>Controlling the False Discovery Rate: A Practical and Powerful
                        Approach to Multiple Testing.</article-title>
                    <source>J Roy Stat Soc B Met</source>
                    <volume>57</volume>
                    <fpage>289</fpage>
                    <lpage>300</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Kamburov1">
                <label>20</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Kamburov</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Wierling</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lehrach</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Herwig</surname>
                            <given-names>R</given-names>
                        </name>
                    </person-group>
                    <year>2009</year>
                    <article-title>ConsensusPathDB–a database for integrating human functional
                        interaction networks.</article-title>
                    <source>Nucl Acids Res</source>
                    <volume>37</volume>
                    <fpage>D623</fpage>
                    <lpage>628</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Kanehisa1">
                <label>21</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Kanehisa</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Goto</surname>
                            <given-names>S</given-names>
                        </name>
                    </person-group>
                    <year>2000</year>
                    <article-title>KEGG: Kyoto Encyclopedia of Genes and Genomes.</article-title>
                    <source>Nucl Acids Res</source>
                    <volume>28</volume>
                    <fpage>27</fpage>
                    <lpage>30</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-JoshiTope1">
                <label>22</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Joshi-Tope</surname>
                            <given-names>G</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Gillespie</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Vastrik</surname>
                            <given-names>I</given-names>
                        </name>
                        <name name-style="western">
                            <surname>D'Eustachio</surname>
                            <given-names>P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Schmidt</surname>
                            <given-names>E</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2005</year>
                    <article-title>Reactome: a knowledgebase of biological pathways.</article-title>
                    <source>Nucl Acids Res</source>
                    <volume>33</volume>
                    <fpage>D428</fpage>
                    <lpage>432</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Romero1">
                <label>23</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Romero</surname>
                            <given-names>P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Wagg</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Green</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kaiser</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Krummenacker</surname>
                            <given-names>M</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2004</year>
                    <article-title>Computational prediction of human metabolic pathways from the
                        complete human genome.</article-title>
                    <source>Genome Biol</source>
                    <volume>6</volume>
                    <fpage>R2</fpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Schaefer1">
                <label>24</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Schaefer</surname>
                            <given-names>CF</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Anthony</surname>
                            <given-names>K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Krupa</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Buchoff</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Day</surname>
                            <given-names>M</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>PID: the Pathway Interaction Database.</article-title>
                    <source>Nucl Acids Res</source>
                    <volume>37</volume>
                    <fpage>D674</fpage>
                    <lpage>679</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Hande1">
                <label>25</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Hande</surname>
                            <given-names>KR</given-names>
                        </name>
                    </person-group>
                    <year>1998</year>
                    <article-title>Etoposide: four decades of development of a topoisomerase II
                        inhibitor.</article-title>
                    <source>Eur J Cancer</source>
                    <volume>34</volume>
                    <fpage>1514</fpage>
                    <lpage>1521</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Minotti1">
                <label>26</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Minotti</surname>
                            <given-names>G</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Menna</surname>
                            <given-names>P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Salvatorelli</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Cairo</surname>
                            <given-names>G</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Gianni</surname>
                            <given-names>L</given-names>
                        </name>
                    </person-group>
                    <year>2004</year>
                    <article-title>Anthracyclines: Molecular Advances and Pharmacologic Developments
                        in Antitumor Activity and Cardiotoxicity.</article-title>
                    <source>Pharmacol Rev</source>
                    <volume>56</volume>
                    <fpage>185</fpage>
                    <lpage>229</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Hsu1">
                <label>27</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Hsu</surname>
                            <given-names>PP</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sabatini</surname>
                            <given-names>DM</given-names>
                        </name>
                    </person-group>
                    <year>2008</year>
                    <article-title>Cancer Cell Metabolism: Warburg and Beyond.</article-title>
                    <source>Cell</source>
                    <volume>134</volume>
                    <fpage>703</fpage>
                    <lpage>707</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Mazurek1">
                <label>28</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Mazurek</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Boschek</surname>
                            <given-names>CB</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hugo</surname>
                            <given-names>F</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Eigenbrodt</surname>
                            <given-names>E</given-names>
                        </name>
                    </person-group>
                    <year>2005</year>
                    <article-title>Pyruvate kinase type M2 and its role in tumor growth and
                        spreading.</article-title>
                    <source>Semin in Cancer Biol</source>
                    <volume>15</volume>
                    <fpage>300</fpage>
                    <lpage>308</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-DeBerardinis1">
                <label>29</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>DeBerardinis</surname>
                            <given-names>RJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Mancuso</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Daikhin</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Nissim</surname>
                            <given-names>I</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Yudkoff</surname>
                            <given-names>M</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2007</year>
                    <article-title>Beyond aerobic glycolysis: Transformed cells can engage in
                        glutamine metabolism that exceeds the requirement for protein and nucleotide
                        synthesis.</article-title>
                    <source>Proc Natl Acad Sci USA</source>
                    <volume>104</volume>
                    <fpage>19345</fpage>
                    <lpage>19350</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Simons1">
                <label>30</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Simons</surname>
                            <given-names>AL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ahmad</surname>
                            <given-names>IM</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Mattson</surname>
                            <given-names>DM</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Dornfeld</surname>
                            <given-names>KJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Spitz</surname>
                            <given-names>DR</given-names>
                        </name>
                    </person-group>
                    <year>2007</year>
                    <article-title>2-Deoxy-d-Glucose Combined with Cisplatin Enhances Cytotoxicity
                        via Metabolic Oxidative Stress in Human Head and Neck Cancer
                        Cells.</article-title>
                    <source>Cancer Res</source>
                    <volume>67</volume>
                    <fpage>3364</fpage>
                    <lpage>3370</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Kartalou1">
                <label>31</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Kartalou</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Essigmann</surname>
                            <given-names>JM</given-names>
                        </name>
                    </person-group>
                    <year>2001</year>
                    <article-title>Mechanisms of resistance to cisplatin.</article-title>
                    <source>Mutat Res-Fund Mol M</source>
                    <volume>478</volume>
                    <fpage>23</fpage>
                    <lpage>43</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Siddik1">
                <label>32</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Siddik</surname>
                            <given-names>ZH</given-names>
                        </name>
                    </person-group>
                    <year>2003</year>
                    <article-title>Cisplatin: mode of cytotoxic action and molecular basis of
                        resistance.</article-title>
                    <source>Oncogene</source>
                    <volume>22</volume>
                    <fpage>7265</fpage>
                    <lpage>7279</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Wernyj1">
                <label>33</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Wernyj</surname>
                            <given-names>RP</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Morin</surname>
                            <given-names>PJ</given-names>
                        </name>
                    </person-group>
                    <year>2004</year>
                    <article-title>Molecular mechanisms of platinum resistance: still searching for
                        the Achilles' heel.</article-title>
                    <source>Drug Resist Update</source>
                    <volume>7</volume>
                    <fpage>227</fpage>
                    <lpage>232</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Preston1">
                <label>34</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Preston</surname>
                            <given-names>TJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Henderson</surname>
                            <given-names>JT</given-names>
                        </name>
                        <name name-style="western">
                            <surname>McCallum</surname>
                            <given-names>GP</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Wells</surname>
                            <given-names>PG</given-names>
                        </name>
                    </person-group>
                    <year>2009</year>
                    <article-title>Base excision repair of reactive oxygen species‚ initiated
                        7,8-dihydro-8-oxo-2-deoxyguanosine inhibits the cytotoxicity of platinum
                        anticancer drugs.</article-title>
                    <source>Mol Cancer Ther</source>
                    <volume>8</volume>
                    <fpage>2015</fpage>
                    <lpage>2026</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Goodisman1">
                <label>35</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Goodisman</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hagrman</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tacka</surname>
                            <given-names>K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Souid</surname>
                            <given-names>A-K</given-names>
                        </name>
                    </person-group>
                    <year>2006</year>
                    <article-title>Analysis of cytotoxicities of platinum compounds.</article-title>
                    <source>Cancer Chemoth Pharm</source>
                    <volume>57</volume>
                    <fpage>257</fpage>
                    <lpage>267</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Koehler1">
                <label>36</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Koehler</surname>
                            <given-names>SE</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ladner</surname>
                            <given-names>RD</given-names>
                        </name>
                    </person-group>
                    <year>2004</year>
                    <article-title>Small Interfering RNA-Mediated Suppression of dUTPase Sensitizes
                        Cancer Cell Lines to Thymidylate Synthase Inhibition.</article-title>
                    <source>Mol Pharmacol</source>
                    <volume>66</volume>
                    <fpage>620</fpage>
                    <lpage>626</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Kowalski1">
                <label>37</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Kowalski</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Pendyala</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Daignan-Fornier</surname>
                            <given-names>B</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Howell</surname>
                            <given-names>SB</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Huang</surname>
                            <given-names>R-Y</given-names>
                        </name>
                    </person-group>
                    <year>2008</year>
                    <article-title>Dysregulation of Purine Nucleotide Biosynthesis Pathways
                        Modulates Cisplatin Cytotoxicity in Saccharomyces
                        cerevisiae.</article-title>
                    <source>Mol Pharmacol</source>
                    <volume>74</volume>
                    <fpage>1092</fpage>
                    <lpage>1100</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Tatidis1">
                <label>38</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Tatidis</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Masquelier</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Vitols</surname>
                            <given-names>S</given-names>
                        </name>
                    </person-group>
                    <year>2002</year>
                    <article-title>Elevated uptake of low density lipoprotein by drug resistant
                        human leukemic cell lines.</article-title>
                    <source>Biochem Pharmacol</source>
                    <volume>63</volume>
                    <fpage>2169</fpage>
                    <lpage>2180</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Shah1">
                <label>39</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Shah</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Flonne</surname>
                            <given-names>W</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Marie-France</surname>
                            <given-names>P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Paul</surname>
                            <given-names>TW</given-names>
                            <suffix>Jr</suffix>
                        </name>
                        <name name-style="western">
                            <surname>Kristine</surname>
                            <given-names>G</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2010</year>
                    <article-title>Choline kinase overexpression increases invasiveness and drug
                        resistance of human breast cancer cells.</article-title>
                    <source>NMR Biomed</source>
                    <volume>23</volume>
                    <fpage>633</fpage>
                    <lpage>642</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Riedel1">
                <label>40</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Riedel</surname>
                            <given-names>RF</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Porrello</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Pontzer</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Chenette</surname>
                            <given-names>EJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hsu</surname>
                            <given-names>DS</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2008</year>
                    <article-title>A genomic approach to identify molecular pathways associated with
                        chemotherapy resistance.</article-title>
                    <source>Mol Cancer Ther</source>
                    <volume>7</volume>
                    <fpage>3141</fpage>
                    <lpage>3149</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Heijne2">
                <label>41</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Heijne</surname>
                            <given-names>WHM</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lamers</surname>
                            <given-names>R-JAN</given-names>
                        </name>
                        <name name-style="western">
                            <surname>van Bladeren</surname>
                            <given-names>PJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Groten</surname>
                            <given-names>JP</given-names>
                        </name>
                        <name name-style="western">
                            <surname>van Nesselrooij</surname>
                            <given-names>JHJ</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2005</year>
                    <article-title>Profiles of Metabolites and Gene Expression in Rats with
                        Chemically Induced Hepatic Necrosis.</article-title>
                    <source>Toxicol Pathol</source>
                    <volume>33</volume>
                    <fpage>425</fpage>
                    <lpage>433</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Rantalainen2">
                <label>42</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Rantalainen</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Cloarec</surname>
                            <given-names>O</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Beckonert</surname>
                            <given-names>O</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Wilson</surname>
                            <given-names>ID</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Jackson</surname>
                            <given-names>D</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2006</year>
                    <article-title>Statistically Integrated Metabonomic-Proteomic Studies on a Human
                        Prostate Cancer Xenograft Model in Mice.</article-title>
                    <source>J Proteome Res</source>
                    <volume>5</volume>
                    <fpage>2642</fpage>
                    <lpage>2655</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Hirai2">
                <label>43</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Hirai</surname>
                            <given-names>MY</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Klein</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Fujikawa</surname>
                            <given-names>Y</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Yano</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Goodenowe</surname>
                            <given-names>DB</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2005</year>
                    <article-title>Elucidation of gene-to-gene and metabolite-to-gene networks in
                        arabidopsis by integration of metabolomics and
                        transcriptomics.</article-title>
                    <source>J Biol Chem</source>
                    <volume>280</volume>
                    <fpage>25590</fpage>
                    <lpage>25595</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Bradley1">
                <label>44</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Bradley</surname>
                            <given-names>PH</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Brauer</surname>
                            <given-names>MJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Rabinowitz</surname>
                            <given-names>JD</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Troyanskaya</surname>
                            <given-names>OG</given-names>
                        </name>
                    </person-group>
                    <year>2009</year>
                    <article-title>Coordinated concentration changes of transcripts and metabolites
                        in Saccharomyces cerevisiae.</article-title>
                    <source>PLoS Comp Bio</source>
                    <volume>5</volume>
                    <fpage>e1000270</fpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Gibon1">
                <label>45</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Gibon</surname>
                            <given-names>Y</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Usadel</surname>
                            <given-names>B</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Blaesing</surname>
                            <given-names>O</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kamlage</surname>
                            <given-names>B</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hoehne</surname>
                            <given-names>M</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2006</year>
                    <article-title>Integration of metabolite with transcript and enzyme activity
                        profiling during diurnal cycles in Arabidopsis rosettes.</article-title>
                    <source>Genome Biol</source>
                    <volume>7</volume>
                    <fpage>R76</fpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Ashburner1">
                <label>46</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Ashburner</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ball</surname>
                            <given-names>CA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Blake</surname>
                            <given-names>JA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Botstein</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Butler</surname>
                            <given-names>H</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2000</year>
                    <article-title>Gene Ontology: tool for the unification of
                        biology.</article-title>
                    <source>Nat Genet</source>
                    <volume>25</volume>
                    <fpage>25</fpage>
                    <lpage>29</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Williams1">
                <label>47</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Williams</surname>
                            <given-names>PD</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Cheon</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Havaleshko</surname>
                            <given-names>DM</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Jeong</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Cheng</surname>
                            <given-names>F</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>Concordant Gene Expression Signatures Predict Clinical Outcomes
                        of Cancer Patients Undergoing Systemic Therapy.</article-title>
                    <source>Cancer Res</source>
                    <volume>69</volume>
                    <fpage>8302</fpage>
                    <lpage>8309</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Clayton1">
                <label>48</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Clayton</surname>
                            <given-names>AT</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lindon</surname>
                            <given-names>JC</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Cloarec</surname>
                            <given-names>O</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Antti</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Charuel</surname>
                            <given-names>C</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2006</year>
                    <article-title>Pharmaco-metabonomic phenotyping and personalized drug
                        treatment.</article-title>
                    <source>Nature</source>
                    <volume>440</volume>
                    <fpage>1073</fpage>
                    <lpage>1077</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Clayton2">
                <label>49</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Clayton</surname>
                            <given-names>TA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Baker</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lindon</surname>
                            <given-names>JC</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Everett</surname>
                            <given-names>JR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Nicholson</surname>
                            <given-names>JK</given-names>
                        </name>
                    </person-group>
                    <year>2009</year>
                    <article-title>Pharmacometabonomic identification of a significant
                        host-microbiome metabolic interaction affecting human drug
                        metabolism.</article-title>
                    <source>Proc Natl Acad Sci USA</source>
                    <volume>106</volume>
                    <fpage>14728</fpage>
                    <lpage>14733</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Winnike1">
                <label>50</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Winnike</surname>
                            <given-names>JH</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Li</surname>
                            <given-names>Z</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Wright</surname>
                            <given-names>FA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Macdonald</surname>
                            <given-names>JM</given-names>
                        </name>
                        <name name-style="western">
                            <surname>O'Connell</surname>
                            <given-names>TM</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2010</year>
                    <article-title>Use of Pharmaco-Metabonomics for Early Prediction of
                        Acetaminophen–Induced Hepatotoxicity in Humans.</article-title>
                    <source>Clin Pharmacol Ther</source>
                    <volume>88</volume>
                    <fpage>45</fpage>
                    <lpage>51</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Keun1">
                <label>51</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Keun</surname>
                            <given-names>HC</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sidhu</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Pchejetski</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lewis</surname>
                            <given-names>JS</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Marconell</surname>
                            <given-names>H</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>Serum Molecular Signatures of Weight Change during Early Breast
                        Cancer Chemotherapy.</article-title>
                    <source>Clin Cancer Res</source>
                    <volume>15</volume>
                    <fpage>6716</fpage>
                    <lpage>6723</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Sreekumar1">
                <label>52</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Sreekumar</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Poisson</surname>
                            <given-names>LM</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Rajendiran</surname>
                            <given-names>TM</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Khan</surname>
                            <given-names>AP</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Cao</surname>
                            <given-names>Q</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>Metabolomic profiles delineate potential role for sarcosine in
                        prostate cancer progression.</article-title>
                    <source>Nature</source>
                    <volume>457</volume>
                    <fpage>910</fpage>
                    <lpage>914</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Apweiler1">
                <label>53</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Apweiler</surname>
                            <given-names>R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bairoch</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Wu</surname>
                            <given-names>CH</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Barker</surname>
                            <given-names>WC</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Boeckmann</surname>
                            <given-names>B</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2004</year>
                    <article-title>UniProt: the Universal Protein knowledgebase.</article-title>
                    <source>Nucl Acids Res</source>
                    <volume>32</volume>
                    <fpage>D115</fpage>
                    <lpage>119</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Degtyarenko1">
                <label>54</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Degtyarenko</surname>
                            <given-names>K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Matos</surname>
                            <given-names>Pd</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ennis</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hastings</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Zbinden</surname>
                            <given-names>M</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2007</year>
                    <article-title>ChEBI: a database and ontology for chemical entities of
                        biological interest.</article-title>
                    <source>Nucl Acids Res</source>
                    <volume>36</volume>
                    <fpage>D344</fpage>
                    <lpage>50</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1001113-Oliveros1">
                <label>55</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Oliveros</surname>
                            <given-names>JC</given-names>
                        </name>
                    </person-group>
                    <year>2007</year>
                    <article-title>VENNY. An interactive tool for comparing lists with Venn
                        Diagrams.</article-title>
                    <comment>Available: <ext-link ext-link-type="uri" xlink:href="http://bioinfogp.cnb.csic.es/tools/venny/index.html" xlink:type="simple">http://bioinfogp.cnb.csic.es/tools/venny/index.html</ext-link></comment>
                </element-citation>
            </ref>
        </ref-list>
        
    </back>
</article>